Moderna Inc to Discuss Vaccine Against COVID-19 (mRNA-1273) Phase 1 Interim Results Publication Corporate Call Transcript
Good morning, and welcome to Moderna's conference call. (Operator Instructions) Please be advised that the call is being recorded.
At this time, I'd like to turn the call over to Lavina Talukdar, Head, Investor Relations at Moderna. Please proceed.
Thank you, Shannon. Good morning, everyone, and welcome to Moderna's conference call to discuss the publication of our Phase I interim analysis for mRNA-1273, our vaccine against the novel coronavirus. You can access the press release issued this morning as well as the slides that we'll be reviewing by going to the Investors section of our website.
On today's call are Stéphane Bancel, our Chief Executive Officer; Tal Zaks, our Chief Medical Officer; and Stephen Hoge, our President. Also on the line for the Q&A section is David Meline, our Chief Financial Officer.
Before we begin, please note that this conference call will include forward-looking statements made pursuant to the safe harbor provisions of the Private Securities Litigation
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |